New inhaled psychedelic drug GH001 enters first human safety trial
NCT ID NCT07540494
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will give a single inhaled dose of GH001 (5-MeO-DMT) to 12 healthy adults. Researchers will measure how the drug moves through the body and check for any side effects. The goal is to gather basic safety information needed before testing the drug in people with medical conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GH001 (5-MeO-DMT, also known as mebufotenin)
- What this could lead to
- If successful, this study will provide essential safety and dosing data for future trials of GH001 in patients with certain medical conditions.
- What could go wrong
- This is an early Phase 1 trial in only 12 healthy people, so results may not predict effects in patients. The drug is a psychedelic compound and may cause temporary psychological or physical side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GH Research Clinical Trial Site
Miami, Florida, 33319, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody tame the Body's allergic alarm system?
- Fingerprint sweat could replace oral swabs for drug testing
- Wearable tech puts hormone health to the test
- Can a better hazmat suit keep first responders safer and more effective?
- Home video tracking may expose the gap between clinic walking and real-world walking after stroke
- Avocado at breakfast: a secret weapon for blood sugar and fullness?